What was your consortium's most significant achievement from the past year?
Darius Ebrahimi-Fakhari, MD, PhD, Principal Investigator, SP-CERN: In its first year, SP-CERN enrolled more than 160 participants across the network—a pace that establishes the largest prospective cohort assembled to date for hereditary spastic paraplegia and positions the consortium to answer natural history and biomarker questions that no single center could address. This recruitment was made possible by the rapid operationalization of the network: harmonized standard operating procedures were established and adopted across all participating sites, three new affiliate sites were added to extend geographic reach and referral capacity, and the consortium completed validation work on a new clinician-reported outcome measure, the modified Spastic Paraplegia Rating Scale (mSPRS), which is now available for use in future interventional trials. Consortium investigators also published more than 10 peer-reviewed papers over the same period, reflecting both the productivity of the network and the collaborative culture it has built.
What did this achievement accomplish?
Dr. Ebrahimi-Fakhari: This work created capabilities that did not previously exist for hereditary spastic paraplegia. A prospectively characterized cohort of this size, assessed under harmonized protocols with a validated outcome measure, supplies the natural history comparator and statistical power needed to design and power interventional trials in disorders too rare for any single center to study. Harmonized standard operating procedures (SOPs) make data and biospecimens directly poolable across sites, enabling cross-site biomarker discovery and genotype-speciic analyses. The three new affiliate sites extend specialized evaluation and research access to families in regions previously without it. Collectively, these outputs shorten the path from gene discovery to therapeutic trial.
How will this impact the rare disease community?
Dr. Ebrahimi-Fakhari: A trial-ready cohort changes what families can reasonably expect—when a therapeutic candidate emerges, the natural history data, validated outcome measure, and eligible participants are already in place, removing the multi-year delay that strands rare disease programs at the point a trial should begin. The methodological outputs are transferable: harmonized SOPs, a cross-site data model, and a template for adapting and validating an outcome measure for a mixed-age rare disease population can be adopted by other ultra-rare consortia rather than rebuilt. For industry and regulators, a characterized prospective cohort with a fit-for-purpose measure lowers the perceived risk of investing in a rare indication, which is often the practical determinant of whether these disorders attract development at all. More broadly, the year demonstrates that a distributed consortium can reach meaningful scale in a disease group where no single center sees enough patients.
How will this advance the goals of your consortium and/or the RDCRN at large?
Dr. Ebrahimi-Fakhari: For our consortium, the first year cleared the prerequisites—cohort, procedures, outcome measure—on which the remaining project period depends, freeing the coming years for genotype-specific progression, biomarker qualfication, and trial design. It also builds assets that support sustainability beyond the current award. For the RDCRN, data collected under harmonized SOPs are structured for DMCC deposition and reuse by investigators outside the network, realizing the model's core leverage: a cohort assembled once and queried many times. The method we used to adapt and validate an outcome measure for a mixed-age, ultra-rare population addresses a rate-limiting problem shared across consortia and is directly transferable, as is our operational experience scaling a distributed network within a single year. The network also trains fellows and junior investigators in multi-site rare disease research, contributing to the pipeline the RDCRN depends on.
